T2 Biosystems Joins Antimicrobials Working Group as First Diagnostic Member
July 27 2017 - 8:58AM
T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the
development of innovative diagnostic products to improve patient
health, announced today that it will join the Antimicrobials
Working Group (AWG) as its first diagnostic member. T2 Biosystems
joins thirteen antimicrobials companies in their mission to combat
drug resistant infections and spur life-saving innovations.
“Diagnostics play a vital role in providing the best possible
patient care and combatting the global health threat of
antimicrobial resistance,” said Jeffrey Stein, Ph.D., president and
chief executive officer of Cidara Therapeutics and Chairman of the
AWG. “T2 Biosystems is a leading innovator in the field and their
T2MR detection technology enables the delivery of life-saving
medicines more rapidly to patients and reduces the use of
unnecessary drug exposure. We’re excited to have their expertise in
the fight against superbugs and drug resistant infections.”
The T2Sepsis SolutionTM is a unique approach that combines the
best standard of care with T2 Biosystems’ products, including the
T2Dx® Instrument and the T2Candida® Panel. The T2Sepsis Solution
enables early, targeted treatment, providing clinicians the
confidence to de-escalate or stop unnecessary medications. The
T2Sepsis Solution is proven to reduce the time to effective
treatment for patients, reduce length of stay in the hospital and
ICU, and can lead to significant reductions in unnecessary
medication. In addition, T2 Biosystems’ products may lead to
increased enrollment and effectiveness of our partners’ clinical
trials for new, potentially life-saving medication.
“Now more than ever, it is imperative to use the medications we
have today in a targeted manner to prevent resistance and to hasten
the development of new medications. Diagnostics play an important
role in delivering patients the right treatment and assist in
accelerated clinical trials.” said John McDonough, president and
chief executive officer of T2 Biosystems. “Antimicrobial resistance
is a multi-generational challenge and we are proud to be part of
this important collaboration.”
About T2 Biosystems T2 Biosystems is
dedicated to developing innovative diagnostic products to improve
patient health. With the FDA-cleared T2Dx Instrument and
T2Candida Panel targeting sepsis and a range of additional
products in development, T2 Biosystems is an emerging
leader in the field of in vitro diagnostics. The Company is
utilizing its proprietary T2 Magnetic Resonance technology, or
T2MR, to develop a broad set of applications aimed at lowering
mortality rates, improving patient outcomes and reducing the cost
of healthcare by helping medical professionals make targeted
treatment decisions earlier. T2MR enables the fast and sensitive
detection of pathogens, biomarkers and other abnormalities in a
variety of patient sample types, including whole blood. For more
information, please visit www.t2biosystems.com.
About The Antimicrobials Working Group
AWG was founded in 2012 with the vision of utilizing collective
power to improve the regulatory, investment, and commercial
environment for emerging antibiotics and antifungal companies.
Today, AWG is comprised of fourteen antimicrobials and diagnostics
companies: Amplyx Pharmaceuticals, Arsanis Inc., Cempra Inc.,
Cidara Therapeutics Inc., ContraFect Corporation, Iterum
Therapeutics Ltd., Melinta Therapeutics Inc., Nabriva Therapeutics
US Inc., Paratek Pharmaceuticals Inc., SCYNEXIS Inc., T2 Biosystems
Inc., Theravance Biopharma US Inc., Viamet Pharmaceuticals Inc.,
and Zavante Therapeutics Inc. For more information, please
visit www.antimicrobialsworkinggroup.org.
Forward-Looking Statements This press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements. These forward-looking statements are based on
management's current expectations. These statements are neither
promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements, including, but not
limited to, the performance of the Company's diagnostic products
and the ability to bring such products to market. These and other
important factors could cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release. For more information on risk factors for T2
Biosystems, Inc.’s business, please refer to the Company’s Annual
Report on Form 10-K, filed with the Securities and Exchange
Commission on March 15, 2017, under the heading “Risk
Factors,” and other filings the Company makes with
the Securities and Exchange Commission from time to time.
Any such forward-looking statements represent management's
estimates as of the date of this press release. While the Company
may elect to update such forward-looking statements at some point
in the future, it disclaims any obligation to do so, even if
subsequent events cause its views to change. These forward-looking
statements should not be relied upon as representing the Company's
views as of any date subsequent to the date of this press
release.
Company Contact:
Darlene Deptula-Hicks, T2 Biosystems
SVP & Chief Financial Officer
ddeptula@t2biosystems.com
603-553-5803
Media Contact:
Matthew McKillip, T2 Biosystems
mmckillip@t2biosystems.com
518-577-3466
Investor Contact:
Chris Brinzey, Westwicke Partners
chris.brinzey@westwicke.com
339-970-2843
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Aug 2024 to Sep 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Sep 2023 to Sep 2024